Neurology Alert (Vol. 35, No. 3) - November 1, 2015

Read the Disclosure Information Below, then click “Continue” to begin testing.

Release date: November 2015

Valid through: November 2018

Target Audience

This activity is intended for the neurologist.

Subjects

  • Autoimmune Cerebellar Ataxia — Responses to Treatment
  • Potential Imaging Biomarkers of SUDEP: Can We Predict Sudden Death in Epilepsy?
  • Lower Risk of Parkinson’s Disease After Vagotomy: Implications for Spread of Pathology
  • Botulinum Toxin and Treatment of Spasticity
  • Treatment for Ulnar Neuropathy at the Elbow
  • Stroke Alert: Every 5-minute Delay in Performing Endovascular Reperfusion Results in 1 out of 100 Patients Having a Worse Disability Outcome

Objectives

  • Discuss current scientific data regarding the diagnosis and treatment of neurological disease
  • Discuss the pathogenesis and treatment of pain
  • Describe the basic science of brain function
  • Discuss new information regarding new drugs for commonly diagnosed neurological conditions

Credit Available

Physicians

  • Maximum of 2.25 AMA PRA Category 1 Credits

Sponsor

This activity is sponsored by AHC Media.

Accreditation Statement

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Physicians

AHC Media designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing

Authors

Ulrike W. Kaunzner, MD, Fellow in Neurology, Weill Cornell Medical College

Jai Perumal, MD, Assistant Professor of Neurology, Weill Cornell Medical College

Kimberly Pargeon, MD, Assistant Professor of Clinical Neurology, Weill Cornell Medical College

Claire Henchcliffe, MD, Associate Professor of Neurology and Neuroscience, Weill Cornell Medical College

Joseph E. Safdieh, MD, Assistant Professor of Neurology, Weill Cornell Medical College

Michael Rubin, MD, Professor of Clinical Neurology, Weill Cornell Medical College

Matthew E. Fink, MD, Louis and Gertrude Feil Professor in Clinical Neurology, Chairman, Department of Neurology, Weill Cornell Medical College, Neurologist-in-Chief, New York Presbyterian Hospital

Editors

Medical Editor: Matthew E. Fink, MD, Louis and Gertrude Feil Professor in Clinical Neurology, Chairman, Department of Neurology, Weill Cornell Medical College, Neurologist-in-Chief, New York Presbyterian Hospital

AHC Media Executive Editor: Leslie G. Coplin

Managing Editor: Jonathan Springston

Financial Disclosure

Author Jai Perumal, MD, reports she is on the speakers bureau for Biogen Idec, Teva Pharmaceuticals, Genzyme Corp., and Acorda Therapeutics. Author Claire Henchcliffe, MD, reports she is on the speakers bureau and advisory boards for Teva, IMPAX, and ACADIA; and receives grant/research support from Biogen and Kaneka.

Authors Kimberly Pargeon, MD; Joseph E. Safdieh, MD; and Michael Rubin, MD report no financial relationships relevant to this field of study.

Neurology Alert's editor in chief, Matthew E. Fink, MD; peer reviewer M. Flint Beal, MD; executive editor Leslie Coplin; and associate managing editor Jonathan Springston report no financial relationships relevant to this field of study.

Copyright 2015, AHC Media. All rights reserved.